10月3日 - ** 制药商Esperion ESPR.O股价上涨6.5%至3.09美元
** ESPR称已与印度Dr. Reddy's实验室达成和解 (link)，后者将在2040年4月之前不得在美国销售其胆固醇药物Nexletol和Nexlizet的仿制药。
** 该协议解决了Esperion公司在Dr. Reddy's公司寻求批准其在专利到期前推出仿制药后提起的专利诉讼。
** 今年早些时候，Esperion公司已经与Micro Labs、Hetero USA和Accord Healthcare公司就Nexletol仿制药的类似纠纷达成了和解。
** 截至上次收盘，股价累计上涨 32
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.